Clinical trials: Hepatocellular
Radiofrequency Ablation, Ultrasonography
Added Value of Contrast-enhanced Ultrasonography for Percutaneous Radiofrequency Ablation
Contrast-enhanced ultrasonography (CEUS)-CT/MRI fusion imaging substantially improved the visibility of small tumors that were inconspicuous on both US and US-CT/MRI fusion imaging, contributing to successful percutaneous…
- Conditions
- Radiofrequency Ablation, Ultrasonography, Liver Tumors
- Trial name
- NCT05445973
- Testing
- Percutaneous Radiofrequency Ablation
- Where
- South Korea
- Volunteers
- 248 people
- Sponsor
- Seoul National University Hospital
Tumor Response Rate, Overall Survival
TILA-TACE in Treatment of Hepatocellular Carcinoma
To validate the tumor response rate: in the previous study, the investigators showed that TILA-TACE achieved 100% tumor response rate.
- Trial name
- NCT03910140
- Testing
- TILA-TACE treatment
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hepatocellular Carcinoma, Childhood, Fibrolamellar Carcinoma
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
This research study is studying an immunotherapy drug (pembrolizumab or KEYTRUDA) as a possible treatment for pediatric hepatocellular carcinoma or hepatocellular neoplasm not otherwise specified (HCN NOS).
- Conditions
- Hepatocellular Carcinoma, Childhood, Fibrolamellar Carcinoma, Liver Cancer, Liver Cancer, Pediatric
- Trial name
- NCT04134559
- Testing
- Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Allison O'Neill, MD
Hepatocellular Carcinoma, Hepatoblastoma
T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)
This study is for patients that have a type of cancer that arises from the liver, either called hepatocellular carcinoma or hepatoblastoma.
- Trial name
- NCT04093648
- Testing
- TEGAR T cells, Cytoxan, Fludarabine
- Sponsor
- Baylor College of Medicine
Liver Cancer, Metastatic Cancer
Hepatic Arterial Infusion With Melphalan in Treating Patients With Unresectable Liver Cancer
RATIONALE: Heating melphalan to several degrees above body temperature and infusing it to the affected area directly around the tumor may kill more tumor cells.
- Trial name
- NCT00030082
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma, Obesity
Central Obesity and Hepatocellular Carcinoma
Recurrence and metastases after microwave ablation(MWA) of hepatocellular carcinoma(HCC) are the major factors that influence the survival.
- Conditions
- Hepatocellular Carcinoma, Obesity, Microwave Ablation
- Trial name
- NCT03082378
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese PLA General Hospital
Hepatocellular Carcinoma (HCC), Second Line Treatment
A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma
The goal of this prospective Phase II clinical trial is to evaluate the efficacy and safety of QL1706-based combination therapy in patients with hepatocellular carcinoma (HCC) who have failed prior targeted-immunotherapy (e.g.…
- Trial name
- DRIVE-II (NCT07138885)
- Testing
- HAI-FOLFOX + bevacizumab + QL1706, TACE + bevacizumab + TAS-102 + QL1706
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Sun Yat-sen University
HCC - Hepatocellular Carcinoma
Comparison of Gd-EOB-DTPA-enhanced MRI and Contrast-enhanced Ultrasound for Measuring Tumor Size of Solitary Hepatocellular Carcinoma ≤ 5cm:A Retrospective Study
Knowing the tumor size before operation is of great significance to the choice of treatment methods of surgeons and the prognosis of patients.
- Trial name
- NCT06437457
- Testing
- ceus
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Anhui Medical University
Pediatric Cancer, Solid Tumors
A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors
This study is looking to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of lyso-thermosensitive liposomal doxorubicin (LTLD) administered in combination with MR-HIFU in children with…
- Conditions
- Pediatric Cancer, Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma
- Trial name
- NCT02536183
- Testing
- Magnetic resonance high intensity focused ultrasound, Lyso-thermosensitive liposomal doxorubicin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- AeRang Kim
Hepatocellular Carcinoma, Radioembolization
Radioembolization With Yittrium-90 for Intermediate and Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most-common cancer worldwide and the second most-common cause of cancer mortality. Liver resection is the first-line curative treatment for huge HCC.
- Trial name
- NCT02724436
- Testing
- TACE, radioembolization with Y-90
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma, Liver Transplantation
Liver Transplantation With ADV-TK Gene Therapy Improves Survival in Patients With Advanced Hepatocellular Carcinoma
Previous rather poor results in liver transplantation (LT) of patients with advanced hepatocellular carcinoma (HCC) have made the application of LT very limited in treatment of HCC.
- Trial name
- NCT00300521
- Testing
- ADV-TK (adenovirus-thymidine kinase enzyme) gene therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Beijing Chao Yang Hospital
mRNA Vaccination, Hepatocellular Carcinoma
SARS-CoV-2 mRNA Vaccination in Patients With Hepatocellular Carcinoma Treated With Immune Checkpoint Inhibitors
A multicenter retrospective cohort analysis in Austria Primary Objective: To assess whether receiving an mRNA COVID-19 vaccine within 3 months before starting ICI (Immune checkpoint inhibitors) therapy improves best overall…
- Conditions
- mRNA Vaccination, Hepatocellular Carcinoma, Checkpoint Inhibitor
- Trial name
- CoVaCheck (NCT07341321)
- Where
- 5 sites in Austria
- Volunteers
- 200 people
- Sponsor
- Medical University of Graz
Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8
Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma
This trial studies how well yttrium Y 90 glass microspheres work in treating patients with hepatocellular carcinoma that cannot be removed by surgery.
- Conditions
- Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT01176604
- Testing
- Yttrium Y 90 Glass Microspheres
- Where
- United States
- Volunteers
- 299 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumors, Hepatocellular Carcinoma (HCC)
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
In this first-in-human, muticenter, non-randomized, open-label, standard 3+3 dose escalation Phase I study encompasses 5 parts (Part 1-5).
- Conditions
- Solid Tumors, Hepatocellular Carcinoma (HCC), Malignant Melanoma, Pediatric Cancer
- Trial name
- NCT06636435
- Testing
- CBA-1205 Part 1, CBA-1205 Part 2, CBA-1205 Part 3
- Where
- 5 sites in Japan
- Volunteers
- 66 people
- Sponsor
- Chiome Bioscience Inc.
Hepatitis
A Controlled Prospective Study of Transfusion-Associated Hepatitis
This protocol represents a continuation of a series of prospective studies to define the incidence and etiology of transfusion-associated hepatitis (TAH) and to examine the impact on TAH of various modifications in the selection…
- Trial name
- NCT00004848
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Bladder Cancer, Triple Negative Breast Cancer
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in participants with advanced HER3 positive solid tumours.
- Conditions
- Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer
- Trial name
- NCT05057013
- Testing
- HMBD-001, HMBD-001 and enzalutamide
- Where
- 4 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- Cancer Research UK
Solid Tumors
Tabectedin to Treat Children and Adolescents With Cancer
Background: Trabectedin is an experimental drug that kills some cancer cells in the laboratory and in mice by interfering with genetic material (DNA) in cancer cells.
- Trial name
- NCT01453283
- Testing
- Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis
The purpose of this study is to assess the efficacy of Radiofrequency ablation (RFA) and percutaneous acetic acid ablation (PAI) in the management of small hepatocellular carcinoma (HCC) in patients of cirrhosis of liver.
- Trial name
- NCT01438437
- Testing
- PAI, RFA
- Where
- India
- Volunteers
- 54 people
- Sponsor
- All India Institute of Medical Sciences
Hepatocellular Carcinoma, Portal Vein Thrombosis
Surgical Outcome of HCC With Portal Vein Tumor Thrombosis on the Basis of Risk Scoring
The goal of this multicenter retrospective cohort study is to investigate the clinical outcomes and prognostic factors after hepatic resection in patients with HCC exhibiting PVTT, and to develop a prognostic index that can be…
- Conditions
- Hepatocellular Carcinoma, Portal Vein Thrombosis, Prognosis
- Trial name
- NCT06005883
- Where
- South Korea
- Volunteers
- 332 people
- Sponsor
- Keimyung University Dongsan Medical Center
Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
This phase I/II trial studies the side effects and how well nivolumab, fluorouracil, and interferon alpha 2b work for the treatment of fibrolamellar cancer (liver cell cancer) that cannot be removed by surgery (unresectable).
- Conditions
- Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT04380545
- Testing
- Fluorouracil, Nivolumab, Recombinant Interferon Alpha 2b-like Protein
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center